Sleep Disorders

The newest class of medications to treat insomnia have many advantages.

What is the nature of the relationship between psychosis and sleep disorders?

Does early improvement in insomnia predict response to pharmacotherapy in psychotic depression? Authors performed a secondary analysis of a randomized clinical trial.

"Cumulatively, the findings of such reports have led to a concerted effort to encourage physicians to monitor patients for manic symptoms on initiation, reintroduction, and dose modulation of corticosteroid therapy."

What is new in research on sleep?

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

The study explored the intervention’s effects using both quantitative and qualitative methods.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

Researchers investigated the prevalence and correlates of sleep disorders in patients with first-episode psychosis.

What's new in sleep research?

From TMS as a treatment for long COVID to an update on 988 and crisis care, here are highlights from the week in Psychiatric Times.

According to recent research, sleep problems were a common symptom in a large study of patients with first-episode psychosis.

Emergency department records reveal that youth experiencing disrupted sleep are at greater risk for suicidal thoughts and behaviors.

From overutilization of emergency departments to reversible clomiphene-associated manic episodes, here are highlights from the week in Psychiatric Times.

What can we learn from sleep in schizophrenia? New research sheds light.

What risk does clomiphene use present to patients?

How does schizophrenia differ between men and women, and what does this mean for developing treatment strategies?

Test your knowledge on the latest research in sleep issues and schizophrenia.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

New research finds depressive and anxiety symptoms impact effectiveness of cognitive behavioral therapy for insomnia.

From obesity and metabolism in first-episode MDD to psychiatrist liability and suicide, here are highlights from the week in Psychiatric Times.

New positive data was recently released from 5 in vitro studies investigating the potential for drug-drug interaction of mazindol.

From adherence in addiction recovery treatment to the relationship between social media use and youth mental health, here are highlights from the week in Psychiatric Times.

Although more than 90% of children had at least 1 caregiver-reported sleep problem, only 20% had a clinician-documented sleep problem.

Researchers investigated relationships between sleep problems, suicidal ideation, and psychopathology in patients with first-episode psychosis.

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

Sleep experts comment on diagnostic criteria for narcolepsy, factors that may lead to misdiagnosis, and the impact of the condition on a patient’s quality of life.

Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, provide an overview of the pathophysiology of narcolepsy and the role of orexin in regulating the sleep/wakefulness cycle.

Researchers investigated sleep disturbances in individuals at ultra-high risk of psychosis.